Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Proposal of a new grading system for meningioma resection: the Copenhagen Protocol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.

OriginalsprogEngelsk
TidsskriftCancer Investigation
Vol/bind36
Udgave nummer2
Sider (fra-til)165-174
ISSN0735-7907
DOI
StatusUdgivet - 2018

ID: 52644778